We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacterial Test Is Well-Suited for Mid-Sized Labs

By LabMedica International staff writers
Posted on 19 Jul 2018
Print article
Image: The iC-GPC gram-positive assay is a qualitative, multiplex test for the direct detection from positive blood cultures of five of the most common gram-positive bacteria responsible for bacterial bloodstream infections (Photo courtesy of iCubate).
Image: The iC-GPC gram-positive assay is a qualitative, multiplex test for the direct detection from positive blood cultures of five of the most common gram-positive bacteria responsible for bacterial bloodstream infections (Photo courtesy of iCubate).
Bacterial sepsis and its associated complications are a major cause of morbidity and the 10th leading cause of mortality in the USA. Early diagnosis and the institution of appropriate antimicrobial therapy are vital for favorable patient outcomes.

Traditional culture and antimicrobial susceptibility test methods are time dependent processes that often require two to four days before final test results are available. A recently developed assay is an accurate and reliable tool for the detection of the five most common gram-positive bacteria responsible for bloodstream infections.

A team of medical laboratory scientist from different institutions and led by the Laboratory Alliance of Central New York (Syracuse, NY, USA) collected and tested 1,134 patient blood culture clinical specimens from January 2015 until October 2016. Three different automated blood culture systems were evaluated: BacT/ALERT; BACTEC and VersaTREK. These were compared with the iC-GPC assay.

The iC-GPC gram-positive assay is a qualitative, multiplex test for the direct detection from positive blood cultures of five of the most common gram-positive bacteria responsible for bacterial bloodstream infections: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, and Enterococcus faecium. In the multicenter trial, involving testing on patient blood culture specimens that were positive for gram-positive cocci, the assay also detected the presence of mecA, vanA, and vanB resistance determinants.

The iC-GPC Assay had an overall percent agreement with the BC-GP assay of 95.5%. Discordant specimens were further analyzed by a polymerase chain reaction (PCR) and bidirectional sequencing method. The results indicate that the iC-GPC Assay together with the iCubate System is an accurate and reliable tool for the detection of the five most common gram-positive bacteria and their resistance markers responsible for bloodstream infections.

The authors concluded that the iC-GPC Assay provides a significantly more affordable alternative, particularly for small to medium-sized health care institutions, for the molecular detection of common gram-positive bacteria responsible for bloodstream infections and their resistance markers.

Paul A. Granato, PhD, Director of Microbiology and lead author of the study, said, “Traditional methods for the diagnosis or detection of what is causing bloodstream infections, such as septicemia, take two to five days to identify the bacterium and determine what type of antibiotic would be most appropriate for the treatment of a patient.” The study was originally published online on June 13, 2018, in the Journal of Clinical Microbiology.

Related Links:
Laboratory Alliance of Central New York

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.